Eurofins stock tracks two October portfolio deals

Published on 10/07/2026 at 14:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Eurofins stock was trading at EUR 76.26 on October 7, 2026, as two portfolio deals reshaped the group. H1 2026 EPS grew 29 percent and margin expanded 130 basis points.

Extreme Nahaufnahme eines Reagenzglases mit leuchtender DNA-Doppelhelix im Hintergrund — Makroaufnahme von Reagenzglas und DNA-Strang visualisiert die wissenschaftliche Testtätigkeit von Eurofins Scientific SE, ISIN FR0014000MR3, Illustration mit AI erstellt.

Eurofins Scientific SE stock (ISIN FR0014000MR3) was trading at EUR 76.26 on Euronext Paris on October 7, 2026 at 1:58 p.m. CEST, as investors weighed two completed portfolio transactions. The laboratory group acquired Element Materials Technology's North American Life Sciences Testing Services business and sold MET Labs to UL Solutions, both transactions closing on October 1, 2026.

Two deals change the portfolio

According to Eurofins on October 2, 2026, the Element transaction carried an enterprise value of USD 400 million. The acquired business spans 27 laboratories and facilities across North America and is expected to generate annual revenue above USD 150 million in 2026.

The transaction expands Eurofins' BioPharma, environmental and food testing network in the United States and Canada. Its scale matters because the acquired laboratories are being integrated into Eurofins' existing hub-and-spoke platform rather than operated as a standalone asset.

Capital moves toward core testing

Eurofins said on October 2, 2026, that it completed the sale of MET Labs to UL Solutions for an enterprise value of EUR 575 million. The business had approximately 1,300 employees and provided electrical and electronics product safety testing, inspection and certification.

The proceeds are earmarked for debt reduction, laboratory capital expenditure, digital solutions, robotics, artificial intelligence, share buybacks and acquisitions in food, environmental, pharmaceutical and clinical testing. That allocation gives the two transactions a clear strategic contrast: Eurofins is adding scale in life sciences while exiting a non-core testing activity.

H1 progress meets a valuation test

Eurofins reported that H1 2026 adjusted EBITDA margin expanded by 130 basis points and EPS grew 29 percent. The company also maintained its FY 2027 adjusted EBITDA margin objective of 24 percent, according to its investor relations update.

Analyst caution remains part of the valuation picture. Ideal Investisseur reported on September 29, 2026, that Bernstein downgraded Eurofins from Outperform to Market Perform and reduced its price target from EUR 77.20 to EUR 73.90. The target was 3.1 percent below the October 7 trading price, making execution of the acquisitions and the return of organic growth key tests for the 2027 objective.

Eurofins stock holds above EUR 76

Eurofins stock was trading at EUR 76.26 on Euronext Paris on October 7, 2026 at 1:58 p.m. CEST, up 0.16 percent, with a session range of EUR 75.32 to EUR 76.68. The 52-week range was EUR 54.86 to EUR 79.22, while market capitalization stood at EUR 13.2 billion and volume reached 47,074 shares.